NCT06370416 2026-01-28
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
Henan Cancer Hospital
Phase 2 Enrolling by invitation
Clinical Trials
9 trialsNCT03041311 2025-09-25
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
G1 Therapeutics, Inc.
Phase 2 Completed
NCT05578326 2025-07-08
Study of Trilaciclib and Lurbinectidin
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06992739 2025-05-28
PROTECT-2
The First Affiliated Hospital of Xiamen University
Phase 2 Not yet recruiting
NCT06698965 2024-11-21
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Shanghai Chest Hospital
Phase 2 Recruiting
NCT06328049 2024-03-25
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC
Taixing People's Hospital
Phase 2 Recruiting
NCT06297811 2024-03-07
Myeloprotection With Trilaciclib in Pan-cancer Population
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT05900921 2023-06-13
Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer
Sichuan University
Phase 2 Unknown
NCT04863248 2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2 Terminated